Non-penetrating filtering surgery with MMC

Article

Non-penetrating filtering surgery with intraoperative mitomycin C (MMC) and without a scleral implant, can provide reasonable intraocular pressure (IOP) control.

Non-penetrating filtering surgery with intraoperative mitomycin C (MMC) and without a scleral implant, can provide reasonable intraocular pressure (IOP) control, according to Esther Arranz-Marquez and co-workers from the Vissum Corporacion Oftalmologica de Madrid, Spain.

A prospective trial enrolled 131 patients with primary open angle glaucoma (POAG) to undergo non-penetrating filtering surgery with MMC and without an implant. Patients were followed-up at one day and one, three, six, nine and 12 months postoperatively.

Mean preoperative IOP was 20.2±5.2 mmHg. At each follow-up a reduction in IOP was recorded (p=0.001): 12.3±4.2, 13.7±4.6, 13.7±3.6, 14.2±4.0, 14.1±3.6 at one, three, six, nine and 12 months, respectively. Further, the mean number of medications reduced from 1.8±0.7 to 0.1±0.4 12 months postoperatively. Goniopuncture was carried out in 31 eyes and three eyes were re-operated on due to inadequate IOP control.

At the study's conclusion, the authors believed that this procedure offers reasonable IOP control with few postoperative complications.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.